The world's largest pharmaceutical companies by revenue are Johnson & Johnson, Eli Lilly, Pfizer, Roche, Merck & Co, AbbVie, Novartis, AstraZeneca, Sanofi and Novo Nordisk, followed closely by GSK, Bristol Myers Squibb, Takeda, Amgen and Bayer. Exact positions shift each year and depend on what is being counted. But for anyone sourcing pharmaceuticals rather than investing in them, the ranking itself matters far less than a different question: which of these companies' products are losing patent protection, and therefore becoming available as generics. Between 2025 and 2030 an estimated $200–400 billion of branded revenue faces loss of exclusivity — the largest transfer of value from originators to generic manufacturers in the industry's history.
Why published rankings disagree with each other
Search for the largest pharmaceutical companies and you will find lists that contradict one another. The disagreement is methodological, not factual, and it is worth understanding before relying on any of them:
- Total revenue vs pharmaceutical revenue. Johnson & Johnson reports both pharmaceutical and MedTech divisions; Roche includes diagnostics; Bayer includes crop science. A company can rank first on group revenue and fourth on pharmaceutical revenue alone.
- Revenue vs market capitalisation. These produce very different orders. Eli Lilly's valuation has been driven far above its revenue rank by GLP-1 demand.
- Reporting year and currency. Figures published during 2026 are typically 2025 actuals or 2026 guidance, converted at varying exchange rates.
For sourcing purposes, none of this matters much. What matters is which company holds which product, and when that product's protection ends.
The major originators and the brands they hold
If you source generics, these are the companies whose reference brands appear on your specifications. Understanding which originator holds which product is the practical use of this list.
- Johnson & Johnson — immunology and oncology; Stelara (ustekinumab), Darzalex, Xarelto (with Bayer)
- Eli Lilly — metabolic and diabetes; Mounjaro and Zepbound (tirzepatide), Trulicity (dulaglutide), Humalog
- Pfizer — broad portfolio; Eliquis (apixaban, with BMS), Prevnar, Ibrance
- Roche — oncology and biologics; Ocrevus, Perjeta, Avastin and Herceptin (both now widely biosimilar)
- Merck & Co — oncology; Keytruda (pembrolizumab), Januvia (sitagliptin), Gardasil
- AbbVie — immunology; Humira (adalimumab, now biosimilar), Skyrizi, Rinvoq
- Novartis — cardiovascular and oncology; Entresto, Cosentyx, Kisqali
- AstraZeneca — oncology and respiratory; Tagrisso (osimertinib), Farxiga, Symbicort
- Sanofi — immunology and vaccines; Dupixent, Lantus (insulin glargine)
- Novo Nordisk — diabetes and obesity; Ozempic and Wegovy (semaglutide), NovoRapid
- Bristol Myers Squibb — oncology and cardiovascular; Eliquis (apixaban), Opdivo, Revlimid
The generic manufacturers most sourcing actually involves
Lists of "biggest pharmaceutical companies" almost always omit the companies that supply the majority of medicines by volume. For a buyer sourcing finished formulations or APIs, these matter more than the originators:
Global generic and biosimilar leaders: Teva, Viatris, Sandoz.
Indian manufacturers — a substantial share of global generic volume, and the source for most cross-border generic sourcing: Sun Pharma, Dr Reddy's Laboratories, Cipla, Aurobindo Pharma, Lupin, Zydus Lifesciences, Torrent Pharmaceuticals, Glenmark, Alkem, Hetero and Mankind Pharma.
India hosts the largest number of USFDA-compliant manufacturing facilities outside the United States. When a product loses exclusivity, these are typically the companies filing and supplying the generic version — which is why they, rather than the originators, are the relevant names on a sourcing shortlist.
The patent cliff: where the opportunity actually is
This is the section worth reading. Between 2025 and 2030, an estimated $200–400 billion in branded pharmaceutical revenue loses exclusivity. Each expiry converts a protected, high-priced product into a competitive generic or biosimilar market.
Products already in or entering their generic era
- Ustekinumab (Stelara, Johnson & Johnson) — a franchise worth around $10.8 billion; the composition-of-matter patent expired in September 2023 and the biosimilar era began in 2025.
- Adalimumab (Humira, AbbVie) — the reference case for large-scale biosimilar entry, now with multiple biosimilars in major markets.
- Trastuzumab (Herceptin) and bevacizumab (Avastin), both Roche — mature biosimilar markets, widely available from multiple manufacturers.
Major expiries approaching
- Apixaban (Eliquis, Bristol Myers Squibb / Pfizer) — over $10 billion annually. Key US patents run between 2027 and 2029, and Bristol Myers Squibb has indicated it expects generic entry from 1 April 2028.
- Pembrolizumab (Keytruda, Merck & Co) — approximately $29.5 billion in 2023 revenue, the single largest product facing loss of exclusivity. Core US expiry falls around 2028, with first biosimilar approvals widely expected in the 2027–2028 window.
- Nivolumab (Opdivo, Bristol Myers Squibb) — expected to follow a similar path, making Bristol Myers Squibb among the most exposed companies of this cycle.
What this means if you source generics
A patent expiry is not a starting gun; by the time a product is genuinely available, the manufacturers who prepared for it are already supplying. The practical implications:
- Dossier development starts years before expiry. Manufacturers developing a generic for a 2028 expiry are working on it now. If you intend to distribute that product, the conversation with a manufacturer belongs in 2026, not 2028.
- Expiry dates differ by market. A product may be generic in India or Latin America years before the United States or Europe. Patent status is territorial, and the sourcing opportunity often exists in one market long before another.
- Biosimilars are not generics. Small-molecule generics require bioequivalence; biosimilars require comparative analytical and clinical data, far higher investment, and a much smaller field of capable manufacturers. Treat the two as different sourcing problems.
- Early entrants capture the margin. Generic prices fall steeply as competitors enter. The commercial difference between arriving first and arriving third is substantial.
The mistake I see most often: assuming a patent expires everywhere at once
In 25 years of international business development and licensing, the most common and most expensive error I encounter is a buyer who reads that a product has "gone off patent", and begins planning and investing on that basis — without establishing the intellectual property position in the specific country they intend to supply.
Patent protection is territorial. A molecule can be freely manufactured and sold in one market while remaining under full protection in another for years afterwards. Investment decisions made on a headline expiry date, rather than on country-level IP status, lead to product that cannot legally be sold where it was intended to go.
Semaglutide is the clearest current illustration. The compound patent expired on 20 March 2026 across a group of major markets — India, China, Brazil and South Africa among them — with Canada's patent having lapsed separately, and Mexico, Turkey, Saudi Arabia and others in the same 2026 wave. Generic launches followed almost immediately: dozens of brands prepared for the Indian market, and multiple candidates advanced through late-stage trials in China.
In Europe, the position is entirely different. Supplementary Protection Certificates extend exclusivity to approximately 2031. A manufacturer supplying semaglutide legitimately in India in 2026 cannot supply the same product into the European Union for another five years. Around 40% of the world's population now sits in the generic semaglutide era; the remainder, largely the higher-priced markets, will wait years longer.
A buyer who treats "semaglutide is off patent" as a single global fact, and plans an EU launch on that basis, has a serious problem.
What to do instead
- Establish the IP position country by country before committing. Compound patents, secondary patents, formulation and device patents, Supplementary Protection Certificates and regulatory data exclusivity all run on separate clocks and separate territories.
- Obtain a Freedom to Operate (FTO) opinion for each target market. An FTO analysis establishes whether manufacturing, importing and selling the product in that jurisdiction infringes any subsisting right. For any material investment it is not an optional formality — it is the document that determines whether the plan is viable.
- Check regulatory data exclusivity separately from patents. A product can be free of patent protection while still being blocked from registration because the originator's data package remains protected.
- Plan the sequence around the territories, not the molecule. A staged approach — supplying markets as each opens — is usually stronger than waiting for the largest market, and considerably safer than assuming they all open together.
This takes planning time and professional input, and it is the step most often skipped. It is also the step that determines whether a sourcing programme creates value or creates stock that cannot be sold.
Using this in practice
If you are planning a portfolio for the next three to five years, the useful exercise is not studying company rankings but mapping expiries against your target markets: which products lose protection, when, in which territory, and which manufacturers already hold or are developing a dossier for them.
PharmaTradz lists finished formulations, APIs and dossiers available for licensing from verified GMP-certified manufacturers, including products with completed bioequivalence data and dossiers ready for filing in CTD, EU-CTD and ACTD formats.
Browse the product catalogue, review the Global Pharma Demand Index to see what buyers are currently requesting, or post a sourcing requirement to be matched with manufacturers.
Frequently asked questions
Which is the biggest pharmaceutical company in the world?
It depends on the measure. Johnson & Johnson reports the largest total group revenue, having guided to over $100 billion for 2026, though this includes its MedTech division alongside pharmaceuticals. Eli Lilly leads on market capitalisation, driven by demand for its GLP-1 products Mounjaro and Zepbound. On pharmaceutical revenue alone, Johnson & Johnson, Eli Lilly, Pfizer, Roche and Merck & Co consistently occupy the top positions, with order varying by reporting year and methodology.
Which are the largest generic pharmaceutical manufacturers?
Globally, Teva, Viatris and Sandoz are the largest generic and biosimilar producers. India is the largest source of generic medicines by volume, led by Sun Pharma, Dr Reddy's Laboratories, Cipla, Aurobindo Pharma, Lupin and Zydus Lifesciences. For buyers sourcing finished formulations or APIs, these companies are more relevant than the originator list.
Which major drugs are losing patent protection soon?
Pembrolizumab (Keytruda, Merck & Co) faces core US loss of exclusivity around 2028, with biosimilar approvals expected in the 2027–2028 window; it is the largest product in this cycle at roughly $29.5 billion in 2023 revenue. Apixaban (Eliquis, Bristol Myers Squibb and Pfizer) has key US patents expiring between 2027 and 2029, with generic entry expected from April 2028. Ustekinumab (Stelara, Johnson & Johnson) entered its biosimilar era in 2025. Overall, an estimated $200–400 billion in branded revenue loses exclusivity between 2025 and 2030.
What is the difference between a generic and a biosimilar?
A generic is a chemically identical copy of a small-molecule drug and requires bioequivalence data to demonstrate it performs the same way. A biosimilar is a highly similar version of a biological medicine — which cannot be copied exactly because it is produced in living systems — and requires comparative analytical, non-clinical and usually clinical data. Biosimilars cost substantially more to develop, take longer, and are produced by a much smaller group of manufacturers.
Do patents expire at the same time in every country?
No. Patent protection is territorial. A product may be available generically in India, Latin America or parts of Asia years before the same product loses protection in the United States or European Union. Any sourcing decision should confirm patent and regulatory data protection status specifically for the destination market, not assume a global expiry date.
Is semaglutide off patent?
Only in some countries. The semaglutide compound patent expired on 20 March 2026 in a group of markets including India, China, Brazil and South Africa, with Canada's patent having lapsed and Mexico, Turkey, Saudi Arabia and others in the same wave. In the European Union, Supplementary Protection Certificates extend protection to approximately 2031. Semaglutide can therefore be manufactured and sold legitimately in one market while remaining fully protected in another for several more years. Any plan involving semaglutide should be based on the intellectual property position in the specific destination market, confirmed by a Freedom to Operate opinion.
What is a Freedom to Operate (FTO) opinion and when is one needed?
An FTO opinion is a legal analysis establishing whether manufacturing, importing or selling a product in a particular country would infringe any patent or related right in force there. It covers compound patents, secondary and formulation patents, device patents where applicable, Supplementary Protection Certificates and regulatory data exclusivity. It should be obtained for each target market before committing significant investment to a product — particularly for molecules where patent status differs sharply between territories.
How far in advance should sourcing begin before a patent expires?
For small-molecule generics, manufacturers typically begin dossier development two to four years ahead of expiry, so commercial discussions realistically start eighteen months to three years before the date. For biosimilars, development timelines are considerably longer. Buyers who begin conversations after the expiry date has passed generally find that supply is already committed and pricing has moved.
